Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Ital Urol Androl ; 74(2): 69-76, 2002 Jun.
Article in Italian | MEDLINE | ID: mdl-12161940

ABSTRACT

OBJECTIVES: The involvement of vena cava by residual masses after cytoreductive chemotherapy for bulky metastatic germ cell tumors is a rare but possible event. It could ensue by tumor invasion of the inferior vena cava (IVC), venous or neoplastic thrombosis, or by close adherence and encasement of IVC by scar tissue containing fibrosis or cancer; it usually occurs in right testicular neoplasms. In this study we evaluated a group of nine over 86 patients who underwent IVC (and possibly aortic) surgery for post-chemotherapy residual masses and we assessed long term oncological and functional efficacy of the procedure. MATERIALS AND METHODS: Between 1980 and 1997, 86 patients underwent retroperitoneal lymphadenectomy (RPLND) after induction or additional salvage chemotherapy. A subgroup of nine patients, all with primary tumors of the right testis in stage II C to III, showed evidence of caval involvement, four had caval thrombosis, seven exhibited caval invasion; in one case the IVC was displaced and compressed with no clear evidence of infiltration. Surgical management was: three en-bloc and four restricted vena caval resection and two thrombectomy. RESULTS: Of nine patients who underwent IVC surgery, six are alive and have no evidence of disease (follow-up 43-207 months), while three patients deceased for early progression (6-10 months). There were no major surgical complications: only one patient exhibited a significant lymphedema as a result of the primary vascular involvement or of following IVC surgery. CONCLUSIONS: IVC resection is sometimes necessary to complete RPLND of residual masses: it might be crucial to gain oncological clearance, with moderate long term morbidity even for extensive vena cava resections. Among patients eligible for postchemotherapy RPLND, caval involvement selects a higher risk subgroup that should be addressed to medical centers experienced in IVC neoplastic involvement.


Subject(s)
Dysgerminoma/surgery , Testicular Neoplasms/pathology , Thrombectomy , Vena Cava, Inferior/pathology , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bleomycin/administration & dosage , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Collateral Circulation , Combined Modality Therapy , Disease-Free Survival , Dysgerminoma/drug therapy , Dysgerminoma/pathology , Fibrosis , Follow-Up Studies , Humans , Lymph Node Excision , Male , Middle Aged , Necrosis , Neoplasm Invasiveness , Neoplasm, Residual , Radiography , Retroperitoneal Space , Salvage Therapy , Survival Analysis , Testicular Neoplasms/drug therapy , Testicular Neoplasms/surgery , Treatment Outcome , Vena Cava, Inferior/diagnostic imaging , Vena Cava, Inferior/surgery , Venous Thrombosis/etiology , Venous Thrombosis/surgery , Vinblastine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...